P09.41 Single agent Bevacizumab in recurrent glioblastoma after a second line chemotherapy with Fotemustine. The Italian Association of Neuro Oncology experience

Bevacizumab is an anti-VEGF antibody used in the treatment of recurrent glioblastoma (GBM). Despite the available literature, few is known about the best schedule to administer this angiogenesis inhibitor: i) early, at the first recurrence, or ii) later, after a second line of chemotherapy. In this...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Gonnelli, A., Cantarella, M., Molinari, A., Villani, G., Lombardi, G., Fabrini, M., Pace, A., Fabi, A., Pasqualetti, F., Rudà, R., Soffietti, R., Paiar, F.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
POSTER PRESENTATIONS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464262/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.297
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares